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A B S T R A C T
Aim: To examine the inﬂuence of patient’s age and socio-economic status on treatment and outcome in
diffuse large B-cell lymphoma (DLBCL); an aggressive curable cancer, with an incidence rate that
increases markedly with age but varies little with socio-economic status.
Methods: Set within a representative UK population of around 4 million, data are from an established
patient cohort. This report includes all patients (18years) newly diagnosed with DLBCL 2004–2012,
with follow-up to February 2015.
Results: Of the 2137 patients (median age 70.2 years) diagnosed with denovo DLBCL, 1709 (80%) were
treated curatively/intensively and 1161(54.3%) died during follow-up. Five-year overall and relative
survival (RS) estimates were 46.2% (95% CI 44.0–48.4%) and 54.6% (52.1%-57.0%) respectively for all
patients, and 58.5% (56.1–60.9%) and 67.0% (64.3–69.6%) for intensively treated patients. 96.3% of patients
<55 years (366/380) and 96.4% of those with the best performance status (543/563) were treated
curatively: 5-year RSs being 77.9% (73.1–82%) and 87.1% (82.5–90.6%) respectively. At the other end of the
age/ﬁtness spectrum, 33.3% of those 85 years (66/198) and 41.1% with the worst performance (94/225)
were treated curatively: the corresponding 5-year RSs being 50.5% (27.1–69.0%) and 22.9% (14.0–33.2%).
The proportion of patients whose cancer was fully staged fell with increasing age and worsening
performance status. No socio-economic variations with treatment, stage at presentation or outcome
were detected.
Conclusions: Performance status is more discriminatory of survival than chronological age, with ﬁtter
patients beneﬁting from treatment across all ages. Socio-economic factors are not predictive of outcome
in patients with DLBCL in the UK.
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
More than half of all cancers are diagnosed in those aged 70 years
or over in developed regions of the world; and this proportion is
growing as life expectancy increases and populations age [1–3]. That
older cancer patients may be offered less intensive treatments than
their younger counterparts is well known; and although this may be
an informed and appropriate decision, there is concern that in some
cases there may be over reliance on chronological age as a proxy for
other factors which may, or may not, be present [4–6]. Moreover, it
has been suggested that under-treatment of older people could, at
least in part, explain the disparities in cancer survival observed both
within and between countries with seemingly similar health care
systems [7–9]. In this regard, UK cancer services have been at the
centre of many of these discussions; with particular concerns being
raised about equity in the provision of chemotherapy for potentially
curable cancers [6,7,9,10].
In addition to age, there is continued debate about the role that
socioeconomic factors play in determining cancer treatments and
outcomes [11–16]. The underpinning reasons for such health
inequalities are diverse and complex; both in countries like the UK
that have universal health care coverage, and in countries like the
USA that do not [17,18]. In both situations, differentials in general
health and stage at cancer presentation are likely to contribute to
any trends observed; with adequacy of personal insurance
coverage playing an additional role in countries where individuals
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have to pay for their care at the point of delivery [15,19]. However,
as with questions about age biases, the socioeconomic determi-
nants of cancer treatment and survival in the UK continues to be a
topic of public concern and scientiﬁc interest; with recent evidence
suggesting that the persistent differentials seen for many common
cancers may, in fact, be widening [20].
With standardized chemotherapy, and an incidence rate that
does not vary systematically with markers of socio-economic
status but increases exponentially after the age of 55 years [21,22],
diffuse large B-cell lymphoma (DLBCL) is an exemplar cancer
within which to examine treatment and survival variations. DLBCL
is the commonest of the haematological malignancies (leukaemias,
lymphomas and myelomas), accounting for around 48% of all non-
Hodgkin lymphomas [23]. CHOP (cyclophosphamide, doxorubicin,
vincristine, and prednisone) has been the staple chemotherapy for
DLBCL for the last 35 years; the addition of the monoclonal anti-
CD20 antibody Rituximab (R-CHOP) in 2003 increasing the overall
5-year survival to around 60% . However, whilst R-CHOP can be
effective at any age, increasing levels of frailty and comorbidity, as
[24,25] well as decreasing ability to tolerate the side-effects of
intensive chemotherapy, mean that increasing age remains
associated with poorer outcome [24,25].
2. Methods
Data are from the UK’s population-based Haematological
Malignancy Research Network (www.hmrn.org) which, with a
catchment population of nearly 4 million people, has a socio-
demographic composition that broadly mirrors that of the UK as a
whole. Initiated in 2004, full details of its structure, data collection
Box 1. Lymphoma stage, performance status, and symptom deﬁnitions.
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methods and ethical approvals have been previously described
[26]. Brieﬂy, within HMRN patient care is provided by 14 hospitals
organized into ﬁve multi-disciplinary teams (MDTs); and clinical
practice adheres to national guidelines. As a matter of policy, all
diagnoses across the HMRN region are made and coded by clinical
specialists at a single integrated haematopathology laboratory—
the Haematological Malignancy Diagnostic Service (www.hmds.
info); cited in the UK’s Department of Health’s Cancer Reform
Strategy as “the model for delivery of complex diagnostic
services”[27]. HMRN operates with Section 251 support under
the NHS Act 2006, and all patients have prognostic, full-treatment,
response and outcome data collected to clinical trial standards. All
newly diagnosed patients are ‘ﬂagged’ and followed-up for death
and subsequent cancer registrations at the national Medical
Research Information Service (MRIS) and routinely linked to
nationwide information on Hospital Episode Statistics. Area-based
population counts and measures of deprivation are sourced from
the Ofﬁce for National Statistics [21,28].
The present report includes all patients (18 years) newly
diagnosed with denovo DLBCL (n = 2137) between 1st September
2004 and 31st August 2012; all of whom were followed-up until
the 6th February 2015, with primary source information on
presentation, treatment and management including
chemotherapy regimen being obtained directly from medical
records. In accordance with national guidance and other epidemi-
ological studies [29,14,16], the standard measure - income domain
of the national index of deprivation (IMD) [30]—was used as a
marker of socio-economic status; quintile one containing the most
afﬂuent ﬁfth of England’s lower super output areas and quintile
ﬁve the least. Information on cancer stage and patients perfor-
mance status were also used in the analysis: non-Hodgkin
lymphomas being staged using the modiﬁed Ann Arbor system
[31], and performance status graded using the Eastern Oncology
Cooperative Group’s (ECOG) scale [32]. These scores, along with
the indicators used to assess the presence of disease associated
symptoms (B symptoms) are deﬁned in Box 1.
All analyses were conducted using standard analytical methods
in the statistical packages Stata 13 [33] or R [34]; odds ratios were
estimated using logistic regression and time to event analyses by
Cox proportional hazards regression models. The Stata program
strel (v1.2.7) was used to estimate relative survival, which is based
on the maximum likelihood method for individual records
developed by Estève et al [35]; with age and sex-speciﬁc
background mortality rates being obtained from national life
tables [36]. Due to the large number of lymphoma-related deaths
in the ﬁrst year following diagnosis, survival probabilities were
Table 1
Numbers of patient and lymphoma characteristics distributed by ﬁrst-line chemotherapy: HMRN patients (18 years) diagnosed with DLBCL 2004–12
All patients First line chemotherapy with curative intent Odds ratio (95%
Conﬁdence Intervals)
Adjusteda odds ratio
(95% Conﬁdence Intervals)
Yes (%) No (%)
Total 2137 1709 (80.0) 428 (20.0)
Age at diagnosis (years) 18–54 380 366 (96.3) 14 (3.7) 3.99 (2.23–7.15) 3.82 (2.04–7.14)
55–64 388 354 (91.2) 34 (8.8) 1.59 (1.04–2.42) 1.38 (0.86–2.20)
65–74 619 537 (86.8) 82 (13.2) 1 1
75–84 552 386 (69.9) 166 (30.1) 0.35 (0.26–0.47) 0.32 (0.23–0.45)
85 198 66 (33.3) 132 (66.7) 0.08 (0.05–0.11) 0.07 (0.05–0.11)
Median (range) 70.2 (18.3–97.8) 67.4 (18.3–97.7) 80.4 (19.2–97.8)
Trend x2 (P-value) 379.8 (<0.0001) 281.1 (<0.0001)
Sex Males 1117 919 (82.3) 198 (17.7) 1 1
Females 1020 790 (77.5) 230 (22.5) 0.74 (0.60–0.92) 1.05 (0.86–1.37)
Trend x2 (P-value) 7.74 (P = 0.005) 0.13 (P = 0.72)
Patient performance statusc 0 563 543 (96.4) 20 (3.6) 4.35 (2.68–7.08) 3.56 (2.10–6.02)
1 861 742 (86.2) 119 (13.8) 1 1
2 446 308 (69.1) 138 (30.9) 0.36 (0.27–0.47) 0.43 (0.31–0.60)
3 166 75 (45.2) 91 (54.8) 0.13 (0.09–0.19) 0.18 (0.12–0.28)
4 59 19 (32.2) 40 (67.8) 0.08 (0.04–0.14) 0.09 (0.04–0.17)
Not known 42 22 (52.4) 20 (47.6) 0.18 (0.09–0.33) 0.24 (0.11–0.53)
Trend x2 P-value 343.0 (<0.0001)b 178.8 (<0.0001)b
Lymphoma stagec I 338 306 (90.5) 32 (9.5) 2.72 (1.83–4.05) 2.23 (1.44–3.44)
II 375 357 (95.2) 18 (4.8) 5.65 (3.43–9.31) 5.94 (3.42–10.30)
III 281 262 (93.2) 19 (6.8) 3.93 (2.40–6.42) 3.25 (1.92–5.49)
IV 893 695 (77.8) 198 (22.2) 1 1
Not fully staged 250 89 (35.6) 161 (64.4) 0.15 (0.11–0.21) 0.29 (0.20–0.42)
Trend x2 P-value 378.6 (<0.0001)b 171.3 (<0.0001)b
B-symptomsc No 1182 939 (55.0) 243 (56.6) 1 1
Yes 955 770 (45.1) 185 (43.2) 1.07 (0.86–1.32) 1.34 (1.03–1.75)
x
2 P-value 0.40 (0.53) 4.9 (0.03)
Deprivation (quintile) 1 (afﬂuent) 466 383 (82.2) 83 (17.8) 1.06 (0.76–1.47) 1.09 (0.73–1.63)
2 494 402 (81.4) 92 (18.6) 1 1
3 414 325 (78.5) 89 (21.5) 0.82 (0.60–1.14) 0.82 (0.55–1.22)
4 365 283 (77.5) 82 (22.5) 0.79 (0.57–1.10) 0.73 (0.49–1.10)
5 (deprived) 391 312 (79.8) 79 (20.2) 0.90 (0.65–1.26) 0.71 (0.47–1.07)
Not known 7 4 (57.1) 3 (42.9) – –
Trend x2 P-value 4.2 (0.38) 6.3 (0.18)
a Adjusted for all other factors in the table.
b Excludes: not known/not fully staged.
c See deﬁnitions in Box 1.
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initially estimated for monthly intervals and progressively
increased up to yearly intervals until 5-years after diagnosis. In
order to assess the ability of age and performance status to predict
treatment, the receipt of curative chemotherapy was treated as a
binary outcome in logistic regression with age, performance status,
and stage included as explanatory variables. The ability of each
model to predict the receipt of chemotherapy was assessed by
calculating the area under the curve (AUC) of the corresponding
receiver operator curve (ROC).
3. Results
The demographic and clinical characteristics of the 2137
patients (18 years) diagnosed with DLBCL over the eight year
period September 2004-August 2012 are stratiﬁed according to
whether or not they received intensive ﬁrst-line chemotherapy
with curative intent in Table 1. In total, 1709 (80.0%) patients
received such chemotherapy and 428 (20.0%) did not, either
because they died before such treatment could be initiated or the
Table 2
Numbers of deaths, person years and Hazard ratios (HR) distributed by patient, lymphoma and chemotherapy characteristics: HMRN patients ( 18 years) diagnosed with
DLBCL 2004–12 and followed until February 2015.
All patients First line chemotherapy with curative intent
Total Person
years
Alive
(%)
Dead
(%)
Adjusteda
HR (95% Conﬁdence
Intervals)
Total
Person
years
Alive
(%)
Dead
(%)
Adjusteda
HR (95% Conﬁdence
Intervals)
Total 2137 7215 976
(45.7)
1161
(54.3)
1709 6915 957
(56.0)
752
(44.0)
Age at diagnosis (years) 18–54 380 1792 278
(73.2)
102
(26.8)
0.43 (0.35–0.54) 366 1792 278
(76.0)
88
(24.0)
0.46 (0.36–0.58)
55–64 388 1562 223
(57.5)
165
(42.5)
0.74 (0.61–0.89) 354 1524 219
(61.9)
135
(38.1)
0.78 (0.63–0.96)
65–74 619 2181 291
(47.0)
328
(53.0)
1 537 2146 289
(53.8)
248
(46.2)
1
75–84 552 1405 165
(29.9)
387
(70.1)
1.66 (1.43–1.93) 386 1286 154
(39.9)
232
(60.1)
1.53 (1.28–1.83)
85 198 274 19
(9.6)
179
(90.4)
2.10 (1.74–2.54) 66 168 17
(25.8)
49
(74.2)
2.01 (1.48–2.73)
Sex Male 1117 3766 509
(46.5)
608
(54.4)
1 919 3641 500
(54.4)
419
(45.6)
1
Female 1020 3453 467
(45.8)
553
(54.2)
0.89 (0.79–1.01) 790 3274 457
(57.9)
333
(42.1)
0.82 (0.71–0.94)
Patient performance
statusb
0 563 2731 410
(72.8)
153
(27.2)
0.54 (0.45–0.65) 543 2678 405
(74.6)
138
(25.4)
0.60 (0.49–0.74)
1 861 3350 429
(49.8)
432
(50.2)
1 742 3200 418
(56.3)
324
(43.7)
1
2 446 873 104
(23.3)
342
(76.7)
2.04 (1.77–2.36) 308 805 102
(33.1)
206
(66.9)
2.00 (1.67–2.39)
3+4 225 183 20
(8.9)
205
(91.1)
3.79 (3.18–4.50) 94 155 19
(20.2)
75
(79.8)
3.25 (2.52–4.19)
Not known 42 79 13
(31.0)
29
(69.0)
– 22 77 13
(59.1)
9
(40.9)
–
Lymphoma stageb I 338 1663 232
(68.6)
106
(31.4)
0.35 (0.28–0.43) 306 1555 225
(73.5)
81
(26.5)
0.40 (0.31–0.51)
II 375 1656 225
(60.0)
150
(40.0)
0.46 (0.38–0.55) 357 1643 224
(62.7)
133
(37.3)
0.56 (0.46–0.68)
III 281 1065 142
(50.5)
139
(49.5)
0.68 (0.57–0.82) 262 1060 142
(54.2)
120
(45.8)
0.80 (0.65–0.99)
IV 893 2433 324
(36.3)
569
(63.7)
1 695 2360 319
(45.9)
376
(54.1)
1
Not fully
staged
250 403 53
(21.2)
197
(78.8)
1.08 (0.91–1.28) 89 297 47
(52.8)
42
(47.2)
0.74 (0.53–1.02)
B-symptoms No 1182 4284 579
(49.0)
603
(51.0)
1 939 4056 566
(60.3)
373
(39.7)
1
Yes 955 2932 397
(41.6)
558
(58.4)
1.15 (1.03–1.29) 770 2853 391
(50.8)
379
(49.2)
1.20 (1.04–1.39)
Deprivation (quintile) 1 (afﬂuent) 466 1621 226
(48.5)
240
(51.5)
1.09 (0.92– 1.30) 383 1580 224
(58.5)
159
(41.5)
1.05 (0.85–1.31)
2 494 1716 233
(47.2)
261
(52.8)
1 402 1631 227
(56.5)
175
(43.5)
1
3 414 1395 178
(43.0)
236
(57.0)
1.18 (0.99–1.41) 325 1337 174
(53.5)
151
(46.5)
1.18 (0.94–1.46)
4 365 1180 162
(44.4)
203
(55.6)
1.17 (0.97–1.41) 283 1133 160
(56.5)
123
(43.5)
1.09 (0.87–1.38)
5 (deprived) 391 1290 172
(44.0)
219
(56.0)
1.15 (0.96–1.37) 312 1221 168
(53.8)
144
(46.2)
1.20 (0.96–1.50)
Not known 7 16 5
(71.4)
2
(28.6)
– 4 14 4
(100.0)
– –
a Adjusted for all other factors in the table.
b See deﬁnitions in Box 1.
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decision was taken to manage their disease with a palliative
approach, with radiotherapy only or with single agent chemo-
therapies such as vincristine. Of the patients who received
intensive treatment, 85% were treated with R-CHOP, the
remainder were mainly treated with R-CVP and R-CODOX-M/
R-IVAC. The proportion of patients receiving intensive chemo-
therapy with curative intent varied markedly with three
interconnected characteristics; falling with increasing age
(P < 0.0001), worsening performance status (P < 0.0001), and
increasing cancer stage (P < 0.0001). By comparison, the associa-
tion with the presence of B symptoms was weak (adjusted Odds
Ratio = 1.34, 95% CI 1.03–1.75); and no associations between
intensive chemotherapy administration by sex or area-based
deprivation were detected.
Just over half (1161/2137) of the patients died during the follow-
up period (Table 2): the 5-year overall and relative survivals being
46.2% (95% CI 44.0–48.4%)and 54.6% (95% CI 52.1–57.0%) respectively
(Table 3). Patients treated with intensive chemotherapy had better
survival than the totality, the 5-year overall and relative estimates
increasing to 58.5% (95% CI 56.1–60.9%) and 67.0% (95% CI 64.3–
69.6%) respectively. Age, performance status, and stage were
strongly predicative of outcome; the discrimination being clearest
for performance status, both among all patients and among patients
treated with curative intent (Tables 2 and 3,Fig. 1). By contrast, no
associations with deprivation were observed. Our ﬁndings are
discussed in more detail in the sections below.
3.1. Age at diagnosis & performance status
The proportion of patients treated with curative intent fell
gradually from 96.3% (366/388) in under 54 year olds to 86.8%
(537/619) in 65–74 year olds, before falling more steeply to reach
69.9% (386/552) in 75 to 84 year olds and 33.3% (66/198) in those
aged 85 years or more (Table 1). The pattern with performance
status followed a more linear trend, falling incrementally from
96.4% (543/563) in those with a performance of 0 through to 32.2%
(19/59) in those with a performance status of 4.
The impact of age and performance status on the administra-
tion of chemotherapy with curative intent is shown more clearly in
the jitter plots in Fig. 2: patients receiving chemotherapy are
marked as green dots and those who did not as red triangles.
Among patients whose performance status was zero, age was
highly predictive of non-receipt of chemotherapy (AUC = 94% for a
simple logistic model); and, with a median diagnostic age of
84.5 years, the 20 patients who did not receive chemotherapy
were, on average, older than any other group. Our core abstraction
forms indicate that ten of these patients had a recorded entry in
their medical notes stating their preference to decline intensive
treatment.
Age was less predictive of non-receipt of chemotherapy among
patients whose performance status was greater than zero; the
AUCs for simple logistic regression being 78%, 78%, 75% and 62%
respectively for categories one through to four. The varying effect
of age by performance status was conﬁrmed in logistic regression
with an interaction between age and performance status (P = 2.5
 106 in LR test versus a main effects only model). As can be seen
from Fig. 2, the median age at diagnosis fell as performance status
worsened; from 84.5 years among those in category zero, through
to 76.2 years among those in category four. By contrast, among
those who received chemotherapy, median age increased with
deteriorating performance status from 65.4 years in those who
were category zero through to 72.2 years in those who were
category four. The reasons for non-receipt of chemotherapy among
younger patients with performance status one to four were very
Table 3
Five year overall and relative survival estimates (95% Conﬁdence Intervals) for all patients and those treated with ﬁrst-line chemotherapy with curative intent: HMRN patients
(18 years) diagnosed with DLBCL 2004–12 and followed until February 2015
All patients First line chemotherapy with curative intent
Overall survival Relative survival Overall survival Relative survival
Total 46.2 (44.0–48.4) 54.6 (52.1–57.0) 58.5 (56.1–60.9) 67.0 (64.3–69.6)
Age at diagnosis (years) 18–54 73.7 (68.8–77.9) 74.8 (69.9–79.0) 76.7 (72.0–80.8) 77.9 (73.1–82.0)
55–64 58.7 (53.3–63.6) 61.5 (55.9–66.7) 63.5 (57.9–68.5) 66.5 (60.6–71.7)
65–74 48.5 (44.4–52.5) 54.5 (49.9–58.9) 57.2 (52.7–61.3) 64.1 (59.1–68.6)
75–84 30.3 (26.4–34.3) 41.2 (35.9–46.5) 43.9 (38.7–49.0) 59.3 (52.1–65.9)
 85 8.1 (4.9–12.3) 16.5 (9.9–24.6) 26.4 (15.6–38.6) 50.5 (27.1–69.9)
Sex Males 46.5 (43.4–49.5) 54.9 (51.4–58.3) 57.2 (53.8–60.4) 66.2 (62.4–69.7)
Females 45.8 (42.6–49.0) 54.2 (50.7–57.7) 60.0 (56.4–63.5) 67.9 (64.0–71.6)
Patient performance statusa 0 75.0 (70.9–78.6) 86.6 (82.0–90.1) 76.5 (72.5–80.1) 87.1 (82.5–90.6)
1 53.2 (49.7–56.6) 62.8 (58.9–66.5) 60.7 (57.0–64.2) 69.6 (65.4–73.3)
2 20.9 (17.2–24.8) 25.5 (21.1–30.1) 33.6 (28.2–39.1) 39.1 (32.8–45.3)
3+4 3.2 (1.8–5.0) 3.9 (2.3–6.1) 20.4 (12.5–29.6) 22.9 (14.0–33.2)
Lymphoma stagea I 71.5 (66.0–76.2) 84.5 (78.1–89.1) 75.5 (70.0–80.2) 86.4 (80.0–90.8)
II 64.3 (59.0–69.1) 73.9 (67.9–78.9) 67.4 (62.1–72.2) 76.5 (70.5–81.5)
III 53.2 (47.0–59.1) 61.6 (54.4–68.1) 57.6 (51.1–63.6) 66.3 (58.8–72.7)
IV 35.0 (31.8–38.2) 40.4 (36.9–44.0) 47.3 (43.5–51.1) 53.8 (49.5–57.9)
Not fully staged 14.7 (10.8–19.3) 21.6 (15.9–27.9) 53.8 (41.9–64.2) 66.9 (51.3–78.5)
Deprivation (quintile) 1 (afﬂuent) 48.2 (43.4–52.9) 56.2 (50.8–61.3) 60.1 (54.7–65.0) 68.0 (62.2–73.2)
2 48.0 (43.4–52.5) 56.6 (51.3–61.5) 58.8 (53.6–63.6) 67.6 (61.9–72.7)
3 45.1 (40.1–49.9) 53.0 (47.4–58.4) 58.3 (52.6–63.5) 66.0 (59.7–71.6)
4 44.9 (39.6–50.0) 53.1 (46.9–58.9) 59.7 (53.5–65.3) 68.2 (61.3–74.2)
5 (deprived) 43.8 (38.6–48.9) 53.1 (47.0–58.9) 55.5 (49.5–61.1) 64.5 (57.5–70.6)
a See deﬁnitions in Box 1.
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diverse; and included factors such as the presence of sepsis, serious
co-morbidities, patient refusal, and death before treatment could
be initiated.
Five-year overall and relative survival estimates for all
patients and those treated with curative chemotherapy are
distributed by patient characteristics in Table 3. The 5-year RS of
the 96.3% (366/380) of patients <55 years who were treated
curatively was 77.9% (95% CI 73.1–82%), and that of the 96.4%
(543/563) with a performance status of zero who were also
treated curatively was 87.1% (95% CI 82.5–90.6%). At the other
end of the age and ﬁtness scales, 33.3% (66/198) of those
85 years and 41.8% (94/225) of those with a performance status
of 3/4 were treated curatively: the corresponding 5-year RSs
being 50.5% (95% CI 27.1–69.0%) and 22.9% (14.0–32.2%)
respectively. That the relationship between performance status
and survival is broadly similar within all age strata is illustrated
more clearly by the 5-year relative survival estimates shown in
the top panel of Fig. 3. The importance of performance status is
further evidenced in the bottom panel of Fig. 3, where the 5-year
relative survival estimates are stratiﬁed by age within individual
categories.
3.1.1. Age at diagnosis, stage and deprivation
Two-hundred and ﬁfty patients (11.7%) did not have all of the
investigations required to fully assign stage (Table 1). Staging of
DLBCL requires a bone marrow biopsy as well as a CT and/or PET
scan; and the proportion who did not have all of these
investigations increased markedly after the age of 75 years,
accounting for 42% of the total in those aged 85 years or more
(Supplementary Fig. 1). Furthermore, patient’s performance status
and cancer stage are strongly correlated; with those whose cancer
was not fully staged also tending to have poor performance status.
By contrast, there is no strong evidence of a relationship between
stage at presentation and deprivation. In addition, no association
Fig. 1. Overall and relative survival curves by age, performance status, stage and deprivation for all patients and chemotherapy treated patients: HMRN patients ( 18 years)
diagnosed with DLBCL 2004–12 and followed until February 2015.
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Fig. 2. Jitter plot showing the patients distributed by performance status and age according to whether they received chemotherapy (green dots, with median ages marked
with a green bar) or not (red triangles, with median ages marked with a red bar): HMRN patients (18 years) diagnosed with DLBCL 2004–12. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. 5-year relative survival estimates and 95% conﬁdence intervals stratiﬁed by age and performance status for all patients and chemotherapy treated patients: HMRN
patients (18 years) diagnosed with DLBCL 2004–12 and followed until February 2015.
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between performance status and deprivation was observed (data
not shown).
Supplementary material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.canep.2015.08.015.
4. Discussion
With a median diagnostic age of 70 years, our UK population
based study of 2137 patients newly diagnosed with the aggressive
but curable cancer, diffuse large B-cell lymphoma (DLBCL), found
that general ﬁtness, as measured by performance status, was more
discriminatory of survival than chronological age; with compara-
tively ﬁt patients treated with curative intent beneﬁtting across all
age groups. Furthermore, in contrast to cancers that have strong
environmental/life-style risk factors and/or screening pro-
grammes—such as breast, lung and colorectal cancers—area-based
deprivation was not found to be predictive either of stage at
presentation or of survival. Somewhat paradoxically, the strongest
association between chronological age and treatment with
intensive chemotherapy was seen among the 563 patients with
the best performance status; where the 96.4% of patients treated
with curative intent were, on average, younger than any other
group (median age 65.4 years) and the 20 patients who did not
receive such treatment were, on average, the oldest (median age
83.5 years). However, at least 10 of the 20 patients in this latter
group declined intensive treatment; and in this regard it is
important to note that shared-decision making is a key clearly
deﬁned component of UK healthcare policy, with emphasis placed
on the patient as the ﬁnal arbiter of the management approach that
best suits their preferences, even if this is to decline treatment
[37,38].
Using the same commonly applied index of multiple depriva-
tion as a marker of socio-economic status as used here, we have
previously demonstrated signiﬁcant survival inequalities within
our catchment population for chronic myeloid leukaemia (CML)
[39]; a once rapidly fatal cancer transformed in the early 2000s by
orally administered tyrosine kinase inhibitors into a long-term
condition with a steadily rising prevalence. Unlike CML, which is
controlled by lifelong daily therapy, patients with DLBCL who
survive intensive chemotherapy are considered cured; with those
who are not treated curatively and those who do not respond to
chemotherapy tending to die within a few months of diagnosis.
Hence, the drivers for the socio-economic variations seen within
our population for CML are likely to be very different from those
that could potentially impact on DLBCL.
Whilst no evidence of socio-economic inequalities in stage at
presentation, treatment or survival for DLBCL was found in our UK
population, differences have been reported from elsewhere; most
notably from the USA where pronounced survival disparities
associated with insurance status have been described for many
cancers, including DLBCL [19,40,41]. Contemporary socio-eco-
nomic data on DLBCL from Europe, where personal health
insurance does not exert the same inﬂuence as in the USA, are
sparse. However, the most recent report from Denmark, which
included almost 90% of all lymphoma diagnoses 2000 to 2008,
noted elevated mortality among DLBCL patients of lower socio-
economic status; the authors concluding that delayed presenta-
tion may have had a role to play [42]. That we failed to detect such
differences in our more recent data (diagnoses 2004 to 2012)
could, at least in part, be due to the survival improvements
generated by the introduction of Rituximab in 2003. Rituximab,
which was trialled in patients aged 60–80 years because of its low
toxicity [43], has impacted on DLBCL survival across all ages and
cancer stages; the outcome for patients with delayed presenta-
tion and more advanced disease being much better now than it
was in the past [24,25]. Indeed, in our data whilst patients’ age
and general ﬁtness, as measured by their performance status,
were strongly discriminatory of both intensive chemotherapy and
survival, a positive impact on outcome was clearly evident among
older patients who received curative treatment: the 5-year
relative survival estimates of those surviving the ﬁrst months of
treatment paralleling those of the general population. Undoubt-
edly, the emergence of novel targeted agents like Rituximab has
drawn attention to the fact that the age dichotomizations used in
traditional prognostic scores are no longer as informative as
perhaps they once were [24,25]. In this regard, as well as the
requirement for less toxic and more effective treatments, there is
a clear need for better tools to predict an individual’s tumour
response and their ability to tolerate therapy.
Examining and interpreting socio-demographic differentials is
always challenging, particularly in fast-moving areas of oncology
where treatment protocols are subject to rapid change, and ‘gold
standard’ randomized controlled chemotherapy trials are often
restricted to speciﬁc patient groups; traditionally younger patients
with fewer co-morbidities. The ability to conduct comprehensive
population-based analyses of the type presented here is, however,
a fundamental attribute of the UK’s NHS. Predicated on these
structures, our population-based patient cohort was initiated to
produce ‘real-world’ generalizable data to inform contemporary
clinical practice and research; major strengths including its large
well-deﬁned catchment area, completeness of ascertainment and
world-class diagnostics. Importantly, the socio-demographic
structure of our catchment population, which at around 4 million
accounts for around 6% of the UK’s estimated total, is broadly
representative of the national population in terms of age, sex, and
deprivation; and clinical practice adheres to national guidelines
[21,26]. Crucially in this respect, because all diagnoses within
HMRN are made and coded by clinical experts, our data do not
suffer from the problems commonly encountered by non-specialist
registries, where lymphomas are often registered using not
otherwise speciﬁed (NOS) morphology codes, such as lymphoma
NOS (9590) or non-Hodgkin lymphoma NOS (9591) [44]. In
practice this means that cancer registry sub-type frequencies can
be implausibly low; a recent analysis of routine cancer registra-
tions in the UK reporting, for example, that DLBCL accounted for
only 26% of all non-Hodgkin lymphomass—far less than the 48%
recorded in our specialist registry [23]. Furthermore, our use of
clinical data relating to performance status, cancer stage and
presence of B-symptoms serves to highlight the importance of
incorporating such information into studies examining the impact
of socio-demographic factors on treatment patterns and survival.
In summary, although patient’s age and performance status
(ﬁtness) were predictive of both intensive chemotherapy and
survival; performance status was far more discriminatory of
outcome than age, with ﬁtter patients beneﬁting from treatment
across all age groups. Furthermore, in the UK setting of universal
health-care coverage, we found no evidence that socio-economic
factors were predictive of DLBCL stage at presentation, treatment
or survival. In this regard, data from the Benchmarking
Partnership 1995-2007, conﬁrmed that UK survival for breast,
colorectal, lung and ovarian cancer lagged behind that reported
for Australia, Canada, Norway and Sweden [9]. However, with 80%
of cancer patients in our study being treated with curative intent,
our 5-year relative survival estimates for DLBCL are broadly
comparable to those of other European countries [45,46]. Whilst
this could be due to the fact that UK cancer services have
improved in recent years, it is also possible that the national
survival differences seen for many cancers may not extrapolate
uniformly to all. Accordingly, future comparative analyses of
survival may beneﬁt from the inclusion of potentially curable
cancers, such as DLBCL, which do not have strong environmental
determinants to their aetiology.
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